Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Halozyme Therapeutics Inc (NASDAQ:HALO)

13.39
Delayed Data
As of Apr 24
 +0.105 / +0.79%
Today’s Change
7.70
Today|||52-Week Range
15.20
+35.53%
Year-to-Date

Five Year Financial Summary

Total Revenue

Cash & Short Term Investments

Cash From Operations

All Currency in US Dollars4 Quarter
Trend
Quarter 1
2016
Quarter 2
2016
Quarter 3
2016
Quarter 4
2016
Revenue and IncomeNet Revenues42.5M33.3M31.9M39.0M
 
 
 
 
 
Cost of Goods Sold7.3M7.7M8.5M7.4M
 
 
 
 
 
Depreciation And Amortization489.0K623.0K654.0K644.0K
 
 
 
 
 
 
Operating ExpensesGross Income34.7M25.0M22.7M31.0M
 
 
 
 
 
General Expenses50.9M46.8M45.5M53.6M
 
 
 
 
 
Research And Development40.1M35.5M33.9M41.3M
 
 
 
 
 
Total Operating Expenses58.7M55.1M54.6M61.6M
 
 
 
 
 
 
Non-Operating ExpensesOperating Income-16.2M-21.7M-22.7M-22.6M
 
 
 
 
 
Interest Expense On Debt3.9M5.2M5.3M5.6M
 
 
 
 
 
 
Income Taxes, Minority Interest and Extra ItemsPre-Tax Income-19.8M-26.6M-27.7M-27.8M
 
 
 
 
 
Income Taxes0.00-300.0K-1.3M-422.0K
 
 
 
 
Net Income-19.8M-26.9M-28.9M-27.4M
 
 
 
 
 
 
Shares To Calculate EPSShares To Calculate EPS127.6M128.0M128.2M128.2M
 
 
 
 
 
Shares To Calculate EPS Diluted127.6M128.0M128.2M128.2M
 
 
 
 
 
 
Earnings Per ShareEPS-$0.16-$0.21-$0.23-$0.21
 
 
 
 
 
EPS Diluted-$0.16-$0.21-$0.23-$0.21